Invizyne Technologies selected for $2 million project to advance SAF capabilities

Invizyne Technologies Inc., a designer of cell-free, enzyme-based biomanufacturing systems, announced Nov. 19 it was awarded a $2 million project to enable enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF).

The project is a cost share grant from the U.S. Department of Defense’s BioMADE initiative, in partnership with the University of Georgia.

It is one of 17 BioMADE projects announced Oct. 30 to drive the scale-up and commercialization of American biomanufactured products.

“The next five to 10 years will determine the global leader of the bioeconomy,” said BioMADE CEO Douglas Friedman. “At BioMADE, we believe the U.S. is uniquely positioned to seize this opportunity. We are proud to support these member-driven projects that will translate our country’s rich history of biotechnology innovation into manufacturing leadership. All Americans will benefit from investments in America’s bioindustrial manufacturing future.”  

Prior to the BioMADE grant, Invizyne was awarded a total of $5.85 million in grants from the Bioenergy Technologies Office (BETO) within U.S. DOE’s Office of Energy Efficiency and Renewable Energy to develop its novel cell-free approach for isobutanol production.

Isobutanol is a commodity chemical that can replace conventional petroleum-based fuels like gasoline, according to Invizyne, and serves as a precursor to SAF.

The global SAF market is expected to grow at a compound annual rate of 52.2 percent to reach $27.4 billion by 2032, according to Acumen Research and Consulting.

The latest grant from BioMADE will be used to take the next step toward cell-free biomanufacturing of isobutanol.

Specifically, it will be used to develop an enzyme production and processing pipeline and deploy Invizyne’s technology in 100-liter pilot-scale facilities.

“This initiative could indeed mark the beginning of a new era in sustainable biofuel production, bringing us closer to a greener, more efficient future,” said Paul Opgenorth, a co-founder and vice president of development at Invizyne. “That’s because at its heart, this project seeks to mature the technology-readiness level of our cell-free enzyme approach, enabling the project participants to convert renewable sugars into isobutanol at scale.”

Michael Heltzen, CEO of Invizyne, added, “While the BioMADE project will play a pivotal role in validating the technical and economic feasibility of cell-free isobutanol production, it’s also important to understand that our vision at Invizyne extends beyond biofuel applications. We see this project as establishing a framework for expanding Invizyne’s cell-free approach into various industrial processes too. Now that we have completed our IPO and we are able to continue to mature our technology, I fully believe we can become the leader in next-generation biomanufacturing and dramatically reduce greenhouse-gas emissions and foster a shift toward renewable solutions in the process.”